eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2019
vol. 36
 
Share:
Share:
more
 
 
abstract:
Educational article

New indications for topical ivermectin 1% cream: a case series study

Wioletta Barańska-Rybak, Elżbieta Kowalska-Olędzka

Adv Dermatol Allergol 2019; XXXVI (1): 58-62
Online publish date: 2019/02/22
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Topical ivermectin is an effective treatment for inflammatory papulopustular rosacea in adults. Positive therapeutic effects of ivermectin due to its potential anti-inflammatory properties could be achieved in the other facial dermatoses.

Aim
To assess the efficacy of topical ivermectin 1% cream therapy in mild and moderate perioral dermatitis (PD), seborrheic dermatitis (SD) and acne vulgaris (AV).

Material and methods
The study comprising 20 patients diagnosed with PD (8), SD (8) and AV (4) was conducted between November 2016 and July 2017. Two scales were applied to establish efficacy of the treatment: Investigator Global Assessment score (IGA) and Patient Global Assessment of Treatment (PGA).

Results
All patients responded to the treatment with topical ivermectin very well with a gradual reduction in inflammatory skin lesions. Complete or almost complete clearance (IGA score 0–1) was achieved in 20 cases. Four patients with PD achieved IGA 0–1 after 4 weeks of treatment, 1 patient after 5 weeks, 2 patients after 6 weeks and 1 patient after 12 weeks. In the total group of 8 patients with SD, 4 presented IGA 0 after 4 weeks of therapy, while 4 patients demonstrated IGA 1 after 6 weeks. Patients with AV required 8 and 10 weeks to obtain IGA 1. Nineteen patients of the studied group reported “very good” or “excellent” response to the therapy, only one patient with AV assessed therapy with topical ivermectin as “good”. The adverse events were transient and manifested as mild-moderate desquamation, stinging and burning in 2 patients with PD.

Conclusions
Topical ivermectin was well tolerated and beneficial for treatment of mild and moderate PD, SD and AV.

keywords:

ivermectin, topical, perioral dermatitis, seborrheic dermatitis, acne vulgaris

references:
Burg RW, Miller BM, Baker EE, et al. Avermectin, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother 1979; 15: 361-7.
Crump A, Omura S. Ivermectin, ”wonder drug”, from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87: 13-28.
Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol 2005; 44: 981-8.
Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res 2008; 57: 524-9.
Stein Gold L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double blind vehicle controlled pivotal studies. J Drugs Dermatol 2014; 13: 316-23.
Taieb A, Orthonne JP, Ruzicka T, et al. Superiority of ivermectin 1% cream over metronidazole 0,75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 2015; 172: 1103-10.
Taieb A, Khemis A, Ruzicka T, et al. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0,75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol 2016; 30: 829-36.
Hoffmann E, Dittrich-Breiholz O, Holtmann H, et al. Multiple control of interleukin-8 gene expression. J Leukoc Biol 2002; 72: 847-55.
Thibaut de Mènonville S, Rosignoli C, Soares E, et al. Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex-vivo models. Dermatol Ther 2017; 7: 213-25.
Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 2013; 69: 570-7.
Raedler LA. Soolantra (Ivermectin) 1% cream: a novel, antibiotic-free agent approved for the treatment of patients with rosacea. Am Health Drug Benefits 2015; 8 (Spec Feature): 122-5.
Galderma (Polska) Ltd. Soolantra (ivermectin) 10 mg/g krem – characteristics http://www.galderma.pl
Elston DM. Demodex mites: facts and controversies. Clin Dermatol 2010; 28: 502-4.
Mackenzie CD, Geary TG, Gerlach JA. Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients. Filaria J 2003; (2 Suppl 1): S5.
Zhang X, Song Y, Xiong H, et al. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages . Int Immunopharmacol 2009; 9: 354-9.
Deeks ED. Ivermectin: a review in rosasea. Am J Clin Dermatol 2015; 16: 447-52.
Zargari O, Aghazadeh N, Moeineddin F. Clinical applications of topical ivermectin in dermatology. Dermatol Online J 2016; 22: pii: 13030/qt1kq4p7pp.
Noguera-Morel L, Gerlero P, Torello A, et al. Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: a series of 15 cases. J Am Acad Dermatol 2017; 76: 567-70.
Meinking TL, Mertz-Rivera K, Villar ME, et al. Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation. Int J Dermatol 2013; 52: 106-12.
Miyajima A, Hirota T, Tashiro M, et al. Pharmacokinetics of ivermectin applied topically by whole-body bathing method in healthy volunteers. J Dermatol 2017; 44: 406-13.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe